✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Sodium Polystyrene Sulfonate is a drug marketed by Belcher, Biopharm, Chartwell Rx, Citrusphrma, Cmp Pharma Inc, Epic Pharma Llc, Nuvo Pharms Inc, Pai Holdings Pharm, Ani Pharms, Hikma, Morton Grove, and Roxane. and is included in twelve NDAs.
The generic ingredient in SODIUM POLYSTYRENE SULFONATE is sodium polystyrene sulfonate. There are one thousand four hundred and seventy-two drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the sodium polystyrene sulfonate profile page.
A generic version of SODIUM POLYSTYRENE SULFONATE was approved as sodium polystyrene sulfonate by CMP PHARMA INC on January 19th, 1989.
Summary for SODIUM POLYSTYRENE SULFONATE
Recent Clinical Trials for SODIUM POLYSTYRENE SULFONATE
Identify potential brand extensions & 505(b)(2) entrants
|University of California, Irvine||Phase 4|
|Tris Pharma, Inc.||Phase 4|
|Weill Medical College of Cornell University||Phase 4|